Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy

Novo Nordisk (NVO) stock declined Wednesday, extending recent losses, after the company issued a cautious outlook regarding persistent competition from "unsafe and unlawful" copycat versions of its blockbuster obesity drug, Wegovy. This cautious stance follows a recent cut to its 2025 forecast, despite Wegovy sales soaring 67% to $3.04 billion, surpassing analyst expectations. The drugmaker noted that an estimated 1 million individuals in the U.S. are utilizing compounded GLP-1 drugs, which has negatively impacted Wegovy's penetration within the cash channel, even after the FDA declared branded versions no longer in shortage, a move intended to curb unauthorized compounding.

Analysis

Novo Nordisk (NVO) is facing a significant market disconnect where robust current performance is being overshadowed by forward-looking risks. Despite Wegovy sales surging 67% to $3.04 billion in the June quarter, beating consensus estimates of $2.97 billion, the company's stock fell 3.7% in premarket trading. This negative sentiment is directly attributable to management's cautious guidance regarding sustained competition from "unsafe and unlawful" compounded versions of its GLP-1 drugs. The scale of this issue is substantial, with an estimated one million people in the U.S. using these copies, which management explicitly states has led to lower-than-expected Wegovy penetration in the cash-pay channel. This headwind persists even after the FDA ruled that Wegovy and Eli Lilly's Zepbound are no longer in shortage, a move that should have legally restricted compounders. The market is clearly pricing in the risk that this illicit competition, coupled with last week's reduced 2025 outlook, will materially impact the company's future growth trajectory and ability to fully capitalize on its blockbuster drug.

Key Decisions for Investors

• Investors should weigh Wegovy's impressive 67% sales growth against the material risk that persistent, widespread use of compounded alternatives will continue to erode market share in the lucrative cash-pay segment.
• Monitor developments related to Novo Nordisk's legal and regulatory actions against compounding pharmacies, as success in this area is a key catalyst required to reverse the current negative sentiment and protect its revenue stream.
• Given the stock's sharp reaction to the guidance, consider whether the current valuation fully reflects the compounding risk or if the market has overreacted to a manageable, albeit significant, headwind.
• Evaluate the competitive landscape, including how Eli Lilly (LLY) is addressing similar compounding threats and how companies like Hims & Hers (HIMS) are adapting their business models, as this will influence the entire GLP-1 market.